Compare MLTX & POET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MLTX | POET |
|---|---|---|
| Founded | 2021 | 1972 |
| Country | Switzerland | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Semiconductors |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 2020 | 2008 |
| Metric | MLTX | POET |
|---|---|---|
| Price | $11.62 | $7.46 |
| Analyst Decision | Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $27.50 | N/A |
| AVG Volume (30 Days) | 1.6M | ★ 7.3M |
| Earning Date | 05-07-2026 | 08-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $848.96 |
| Revenue Next Year | N/A | $700.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $6.08 | $3.87 |
| 52 Week High | $23.29 | $20.65 |
| Indicator | MLTX | POET |
|---|---|---|
| Relative Strength Index (RSI) | 29.25 | 43.68 |
| Support Level | $11.06 | $7.00 |
| Resistance Level | $19.24 | $8.09 |
| Average True Range (ATR) | 0.76 | 0.34 |
| MACD | 0.03 | 0.02 |
| Stochastic Oscillator | 7.81 | 10.28 |
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.
POET Technologies Inc is a design and development company offering high-speed optical engines, light source products, and custom optical modules to the artificial intelligence systems market and hyperscale data centers. Its integration solutions are based on the POET Optical Interposer, a novel, patented platform that allows the seamless integration of electronic and photonic devices into a single chip using wafer-level semiconductor manufacturing techniques. POET's Optical Interposer platform also solves device integration challenges across a broad range of communication, computing, and sensing applications. The company operates geographically in the United States, Canada, Singapore and China.